Skip to main content
SpringerLink
Log in

Inhibition of neurogenic inflammation in preventive migraine treatment

  • Chapter
Migraine: A Neuroinflammatory Disease?

Part of the book series: Progress in Inflammation Research ((PIR))

  • 74 Accesses

Abstract

Preventive pharmacological treatment of migraine aims at reducing the frequency, intensity and duration of the attacks by intervening, at the earliest stage possible, in migraine pathogenesis. The medications effective in migraine prevention conceivably act at multiple sites to raise the threshold for spreading cortical depression, to inhibit the mechanisms of vasodilation or neurogenic inflammation, or to enhance central anti-nociception. They most likely work through more than one mode of action and this review will focus on the evidence for an action in inhibiting neurogenic inflammation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ebersberger A, Averbeck B, Messlinger K, Reeh PW (1999) Release of substance P, cal-citonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 89: 901–907

    Article  PubMed  CAS  Google Scholar 

  2. Moskowitz MA (1993) Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 43: S16–S20

    PubMed  CAS  Google Scholar 

  3. Moskowitz MA (1992) Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 13: 307–311

    Article  PubMed  CAS  Google Scholar 

  4. Tuca JO, Planas JM, Parellada PP (1989) Increase in PGE2 and TXA2 in the saliva ofcommon migraine patients. Action of calcium channel blockers. Headache 29: 498–501

    Article  PubMed  CAS  Google Scholar 

  5. Puig-Parellada P, Planas JM, Gimenez J et al (1991) Plasma and saliva levels of PG12 and TXA2 in the headache-free period of classical migraine patients. The effects of nicardipine. Headache 31: 156–158

    Article  PubMed  CAS  Google Scholar 

  6. Chen X, Tanner K, Levine JD (1999) Mechanical sensitization of cutaneous c-fiber nociceptors by prostaglandin E2 in the rat. Neurosci Lett 267: 105–108

    Article  PubMed  CAS  Google Scholar 

  7. Minami T, Okuda-Ashitaka E, Hori Y et al (1999) Involvement of primary afferent c-fibres in touch-evoked pain (allodynia) induced by prostaglandin E2. Eur J Neurosci 11: 1849–1856

    Article  PubMed  CAS  Google Scholar 

  8. Coggeshall RE, Carlton SM (1999) Evidence for an inflammation-induced change in the local glutamatergic regulation of postganglionic sympathetic efferents. Pain 83: 163–168

    Article  PubMed  CAS  Google Scholar 

  9. Ferreira SH (1993) The role of interleukins and nitric oxide in the mediation of inflam-matory pain and its control by peripheral analgesics. Drugs 46 (Suppl) 1: 1–9

    Google Scholar 

  10. Nakamura M, Ferreira SH (1987) A peripheral sympathetic component in inflammatory hyperalgesia. Eur J Pharmacol 135: 145–153

    Article  PubMed  CAS  Google Scholar 

  11. Kinnman E, Levine JD (1995) Involvement of the sympathetic postganglionic neuron in capsaicin-induced secondary hyperalgesia in the rat. Neuroscience 65: 283–291

    Article  PubMed  CAS  Google Scholar 

  12. Khasar SG, Miao FJ, Levine JD (1995) Inflammation modulates the contribution of receptor-subtypes to bradykinin-induced hyperalgesia in the rat. Neuroscience 69: 685–690

    Article  PubMed  CAS  Google Scholar 

  13. Johnson KW, Phebus LA, Cohen ML (1998) Serotonin in migraine: theories, animal models and emerging therapies. Prog Drug Res 51: 219–244

    Article  PubMed  CAS  Google Scholar 

  14. Schmuck K, Ullmer C, Kalkman HO et al (1996) Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache? Eur J Neurosci 8: 959–967

    Article  PubMed  CAS  Google Scholar 

  15. Peroutka SJ (1990) Developments in 5-hydroxytryptamine receptor pharmacology in migraine. Neurol Clin 8: 829–839

    PubMed  CAS  Google Scholar 

  16. Hoyer D, Clarke DE, Fozard JR et al (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46: 157–203

    PubMed  CAS  Google Scholar 

  17. Martin GR, Bolofo ML, Giles H (1992) Inhibition of endothelium-dependent vasorelaxation by arginine analogues: a pharmacological analysis of agonist and tissue dependence. Br J Pharmacol 105: 643–652

    Article  PubMed  CAS  Google Scholar 

  18. Wei EP, Moskowitz MA, Boccalini P, Kontos HA (1992) Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles. Circ Res 70: 1313–1319

    Article  PubMed  CAS  Google Scholar 

  19. Aley KO, McCarter G, Levine JD (1998) Nitric oxide signaling in pain and nociceptor sensitization in the rat. J Neurosci 18: 7008–7014

    PubMed  CAS  Google Scholar 

  20. Yonehara N, Yoshimura M (1999) Effect of nitric oxide on substance P release from the peripheral endings of primary afferent neurons. Neurosci Lett 271: 199–201

    Article  PubMed  CAS  Google Scholar 

  21. Garry MG, Richardson JD, Hargreaves KM (1994) Sodium nitroprusside evokes the release of immunoreactive calcitonin gene-related peptide and substance P from dorsal horn slices via nitric oxide-dependent and nitric oxide-independent mechanisms. J Neurosci 14: 4329–4337

    PubMed  CAS  Google Scholar 

  22. Tournois C, Mutel V, Manivet P et al (1998) Cross-talk between 5-hydroxytryptamine receptors in a serotonergic cell line. Involvement of arachidonic acid metabolism. J Biol Chem 273: 17498–17503

    Article  PubMed  CAS  Google Scholar 

  23. Bonhaus DW, Flippin LA, Greenhouse RJ et al (1999) RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br J Pharmacol 127: 1075–1082

    Article  PubMed  CAS  Google Scholar 

  24. Nelson AD, Wainscott DB, Lucaites VL et al (1997) Selective 5HT2B receptor antagonists block mCPP-induced dural extravasation (abstract). Cephalalgia 17: 342

    Google Scholar 

  25. Moskowitz MA, Macfarlane R (1993) Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 5: 159–177

    PubMed  CAS  Google Scholar 

  26. Cohen Z, Bouchelet I, Olivier A et al (1999) Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization. J Cereb Blood Flow Metab 19: 908–917

    Article  PubMed  CAS  Google Scholar 

  27. Terron JA (1998) Involvement of the 5-HT7 receptor in craniovascular vasodilatation: potential impact in migraine. Proc West Pharmacol Soc 41: 247–251

    PubMed  CAS  Google Scholar 

  28. Terron JA, Falcon-Neri A (1999) Pharmacological evidence for the 5-HT7 receptor mediating smooth muscle relaxation in canine cerebral arteries. Br J Pharmacol 127: 609–616

    Article  PubMed  CAS  Google Scholar 

  29. Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM (1996) Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 14: 35–46

    Article  PubMed  CAS  Google Scholar 

  30. Peroutka SJ (1988) Antimigraine drug interactions with serotonin receptor subtypes in human brain. Ann Neurol 23: 500–504

    Article  PubMed  CAS  Google Scholar 

  31. Moskowitz MA, Waeber C (1997) Neuronal pathophysiology of migraine as a basis for acute treatment with 5-HT receptor ligands. In: H Baumgarten, M Gother (eds): Handbook of experimental pharmacology, volume 128. Springer Verlag, Berlin, 613–635

    Google Scholar 

  32. Cryan JF, Kelliher P, Kelly JP, Leonard BE (1999) Comparative effects of serotonergic agonists with varying efficacy at the 5-HT(1A) receptor on core body temperature: modification by the selective 5-HT(1A) receptor antagonist WAY 100635. J Psychopharmacol 13: 278–283

    Article  PubMed  CAS  Google Scholar 

  33. Ebenezer IS, Parrott RF, Vellucci SV (1999) Effects of the 5-HT1A receptor agonist 8OH-DPAT on operant food intake in food-deprived pigs. Physiol Behav 67: 213–217

    Article  PubMed  CAS  Google Scholar 

  34. Esteban S, Llado J, Sastre-Coll A, Garcia-Sevilla JA (1999) Activation and desensitization by cyclic antidepressant drugs of alpha 2- autoreceptors, alpha 2-heteroreceptors and 5-HT1A-autoreceptors regulating monoamine synthesis in the rat brain in vivo. Naunyn Schmiedebergs Arch Pharmacol 360: 135–143

    Article  PubMed  CAS  Google Scholar 

  35. Markowitz S, Saito K, Moskowitz MA (1988) Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 8: 83–91

    Article  PubMed  CAS  Google Scholar 

  36. Tfelt-Hansen P, Standnes B, Kangasniemi P et al (1984) Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 69: 1–8

    Article  PubMed  CAS  Google Scholar 

  37. Carroll JD, Reidy M, Savundra PA et al (1990) Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses. Cephalalgia 10: 101–105

    Article  PubMed  CAS  Google Scholar 

  38. Ryan RE (1984) Comparative study of nadolol and propranolol in prophylactic treatment of migraine. Am Heart J 108: 1156–1159

    Article  PubMed  Google Scholar 

  39. Stensrud P, Sjaastad 0 (1980) Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine. Headache 20: 204–207

    Article  PubMed  CAS  Google Scholar 

  40. Olsson JE, Behring HC, Forssman B et al (1984) Metoprolol and propranolol in migraine prophylaxis: a double-blind multicenter study. Acta Neurol Scand 70: 160–168

    Article  PubMed  CAS  Google Scholar 

  41. Buzzi MG, Sakas DE, Moskowitz MA (1989) Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 165: 251–258

    Article  PubMed  CAS  Google Scholar 

  42. Kaube H, Hoskin KL, Goadsby PJ (1993) Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 33: 541–544

    Article  PubMed  CAS  Google Scholar 

  43. Ellrich J, Schepelmann K, Pawlak M, Messlinger K (1999) Acetylsalicylic acid inhibits meningeal nociception in rat. Pain 81: 7–14

    Article  PubMed  CAS  Google Scholar 

  44. Diener HC (1999) Efficacy and safety of intravenous acetylsalicylic acid lysinate corn-pared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. Cephalalgia 19: 581–588

    Article  PubMed  CAS  Google Scholar 

  45. Lipton RB, Stewart WF, Ryan RE et al (1998) Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol 55: 210–217

    CAS  Google Scholar 

  46. Buring JE, Peto R, Hennekens CH (1990) Low-dose aspirin for migraine prophylaxis. J Am Med Assoc 264: 1711–1713

    Article  CAS  Google Scholar 

  47. Sances G, Martignoni E, Fioroni L et al (1990) Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 30: 705–709

    Article  PubMed  CAS  Google Scholar 

  48. Welch KM, Ellis DJ, Keenan PA (1985) Successful migraine prophylaxis with naproxen sodium. Neurology 35: 1304–1310

    Article  PubMed  CAS  Google Scholar 

  49. Ziegler DK, Ellis DJ (1985) Naproxen in prophylaxis of migraine. Arch Neurol 42: 582–584

    Article  PubMed  CAS  Google Scholar 

  50. Yaron I, Shirazi I, Judovich R et al (1999) Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum 42: 2561–2568

    Article  PubMed  CAS  Google Scholar 

  51. Couch JR, Hassanein RS (1979) Amitriptyline in migraine prophylaxis. Arch Neurol 36: 695–699

    Article  PubMed  CAS  Google Scholar 

  52. Oguzhanoglu A, Sahiner T, Kurt T, Akalin 0 (1999) Use of amitriptyline and fluoxetine in prophylaxis of migraine and tension-type headaches. Cephalalgia 19: 531–532

    Article  PubMed  CAS  Google Scholar 

  53. Steiner TJ, Ahmed F, Findley LJ et al (1998) S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 18: 283–286

    Article  PubMed  CAS  Google Scholar 

  54. Hashimoto M, Yamamoto Y, Takagi H (1997) Effects of KB-2796 on plasma extravasation following antidromic trigeminal stimulation in the rat. Res Commun Mol Pathol Pharmacol 97: 79–94

    PubMed  CAS  Google Scholar 

  55. Martinez LL, Aparecida DO, Fortes ZB (1999) Influence of verapamil and diclofenac on leukocyte migration in rats. Hypertension 34: 997–1001

    Article  PubMed  CAS  Google Scholar 

  56. Markley HG, Cheronis JC, Piepho RW (1984) Verapamil in prophylactic therapy of migraine. Neurology 34: 973–976

    Article  PubMed  CAS  Google Scholar 

  57. Solomon GD, Steel JG, Spaccavento LJ (1983) Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. J Am Med Assoc 250: 2500–2502

    Article  CAS  Google Scholar 

  58. Sorensen PS, Hansen K, Olesen J (1986) A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia 6: 7–14

    Article  PubMed  CAS  Google Scholar 

  59. Frenken CW, Nuijten ST (1984) Flunarizine, a new preventive approach to migraine. A double-blind comparison with placebo. Clin Neurol Neurosurg 86: 17–20

    Article  CAS  Google Scholar 

  60. Ryan RE (1968) Double-blind crossover comparison of be-105, methysergide and placebo in the prophylaxis of migraine headache. Headache 8: 118–126

    Article  PubMed  CAS  Google Scholar 

  61. Gillies D, Sills M, Forsythe I (1986) Pizotifen (Sanomigran) in childhood migraine. A double-blind controlled trial. Eur Neurol 25: 32–35

    Article  PubMed  CAS  Google Scholar 

  62. Lee WS, Limmroth V, Ayata C et al (1995) Peripheral GABA-A receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol 116: 1661–1667

    Article  PubMed  CAS  Google Scholar 

  63. Klapper J (1997) Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 17: 103–108

    Article  PubMed  CAS  Google Scholar 

  64. Hering R, Kuritzky A (1992) Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 12: 81–84

    Article  PubMed  CAS  Google Scholar 

  65. Pradalier A, Serratrice G, Collard M et al (1989) Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia 9: 247–253

    PubMed  CAS  Google Scholar 

  66. Martin GR (1994) Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmacol Ther 62: 283–324

    Article  PubMed  CAS  Google Scholar 

  67. Peroutka SJ (1990) The pharmacology of current anti-migraine drugs. Headache 30: 5–11

    Article  PubMed  CAS  Google Scholar 

  68. Gobert A, Millan MJ (1999) Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (—) pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors. Neuropsychopharmacology 21: 268–284

    Article  PubMed  CAS  Google Scholar 

  69. Newman-Tancredi A, Chaput C, Gavaudan S et al (1998) Agonist and antagonist actions of (—)pindolol at recombinant, human serotonin 1A (5-HT1A) receptors. Neuropsychopharmacology 18: 395–398

    Article  PubMed  CAS  Google Scholar 

  70. Chugani DC, Niimura K, Chaturvedi S (1999) Increased brain serotonin synthesis in migraine. Neurology 53: 1473–1479

    Article  PubMed  CAS  Google Scholar 

  71. Schoenen J, Maertens DN, Timsit-Berthier M, Timsit M (1986) Contingent negative variation and efficacy of beta-blocking agents in migraine. Cephalalgia 6: 229–233

    Article  PubMed  CAS  Google Scholar 

  72. Saxena PR, Heiligers JP, Villalon CM, Ferrari MD (1992) Effects of tertatolol, a betaadrenoceptor antagonist with agonist affinity at 5-HT1A receptors, in an animal model of migraine: comparison with propranolol and pindolol. Eur J Pharmacol 220: 79–86

    Article  PubMed  CAS  Google Scholar 

  73. Anderson R, Ramafi G, Theron AJ (1996) Membrane stabilizing, anti-oxidative interactions of propranolol and dexpropranolol with neutrophils. Biochem Pharmacol 52: 341–349

    Article  PubMed  CAS  Google Scholar 

  74. Stensrud P, Sjaastad 0 (1974) Clinical trial of a new anti-bradykinin, anti-inflammatory drug, ketoprofen in migraine prophylaxis. Headache 14: 96–100

    Article  PubMed  CAS  Google Scholar 

  75. Johnson RH, Hornabrook RW, Lambie DG (1986) Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. Acta Neurol Scand 73: 490–492

    Article  PubMed  CAS  Google Scholar 

  76. Cashman JN (1996) The mechanisms of action of NSAIDs in analgesia. Drugs 52 (Suppl 5): 13–23

    Article  PubMed  CAS  Google Scholar 

  77. Kurumbail RG, Stevens AM, Gierse JK et al (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384: 644–648

    Article  PubMed  CAS  Google Scholar 

  78. Stuhlmeier KM, Li H, Kao JJ (1999) Ibuprofen: new explanation for an old phenomenon. Biochem Pharmacol 57: 313–320

    Article  PubMed  CAS  Google Scholar 

  79. Carroll JD, Reidy M, Savundra PA et al (1990) Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses. Cephalalgia 10: 101–105

    Article  PubMed  CAS  Google Scholar 

  80. Rouaud C, Delaforge M, Anger-Leroy M et al (1999) The cyclo-oxygenase-dependent regulation of rabbit vein contraction: evidence for a prostaglandin E2-mediated relaxation. Br J Pharmacol 126: 35–44

    Article  PubMed  CAS  Google Scholar 

  81. Rhodes KF, Buckingham JC, Kennard C (1999) The inhibition of nicotine-evoked relaxation of the guinea-pig isolated basilar artery by some analgesic drugs and progesterone. Br J Pharmacol 126: 1003–1008

    Article  PubMed  CAS  Google Scholar 

  82. Chen X, Levine JD (1999) NOS inhibitor antagonism of PGE2-induced mechanical sen-sitization of cutaneous c-fiber nociceptors in the rat. J Neurophysiol 81: 963–966

    PubMed  CAS  Google Scholar 

  83. Harrigan M R, Tuteja S, Neudeck B L (1997) Indomethacin in the management of elevated intracranial pressure: a review. J Neurotrauma 14: 637–650

    Article  PubMed  CAS  Google Scholar 

  84. Castellano A E, Micieli G, Bellantonio P et al. (1998) Indomethacin increases the effect of isosorbide dinitrate on cerebral hemodynamic in migraine patients: pathogenetic and therapeutic implications. Cephalalgia 18: 622–630

    Article  PubMed  CAS  Google Scholar 

  85. Mallet L,Kuyumjian J (1998) Indomethacin-induced behavioral changes in an elder-ly patient with dementia. Ann Pharmacother 32: 201–203

    Article  PubMed  CAS  Google Scholar 

  86. Bromm B, Rundshagen I, Scharein E (1991) Central analgesic effects of acetylsalicylic acid in healthy men. Arzneimittelforschung 41: 1123–1129

    PubMed  CAS  Google Scholar 

  87. Attal N, Kayser V, Eschalier A et al (1988) Behavioural and electrophysiological evidence for an analgesic effect of a non-steroidal anti-inflammatory agent, sodium diclofenac. Pain 35: 341–348

    Article  PubMed  CAS  Google Scholar 

  88. Silberstein SD (1998) Methysergide. Cephalalgia 18: 421–435

    Article  PubMed  CAS  Google Scholar 

  89. Martucci N, Manna V, Agnoli A (1985) Antidepressant drugs and migraine. Cephalalgia 5 (Suppl 2): 225–228

    PubMed  Google Scholar 

  90. Kalkman HO (1994) Is migraine prophylactic activity caused by 5-HT2B or 5-HT2c receptor blockade? Life Sci 54: 641–644

    Article  PubMed  CAS  Google Scholar 

  91. Saxena PR, Verdouw PD (1984) Effects of methysergide and 5-hydroxytryptamine on carotid blood flow distribution in pigs: further evidence for the presence of atypical 5-HT receptors. Br J Pharmacol 82: 817–826

    Article  PubMed  CAS  Google Scholar 

  92. Villalon CM, De Vries P, Rabelo G et al (1999) Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5-HT1B/1D receptors and alpha 2-adrenoceptors. Br J Pharmacol 126: 585–594

    Article  PubMed  CAS  Google Scholar 

  93. Mylecharane EJ (1991) 5-HT2 receptor antagonists and migraine therapy. J Neurol 238 (Suppl 1): S45–S52

    Article  PubMed  Google Scholar 

  94. Eisenach JC, Gebhart GF (1995) Intrathecal amitriptyline acts as an n-methyl-d-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. Anesthesiology 83: 1046–1054

    Article  PubMed  CAS  Google Scholar 

  95. Sukenaga A, Tani E, Fukumori T, Maeda Y (1984) Responses of isolated canine basilar artery and human platelet to chlorpromazine and amitriptyline. Stroke 15: 295–300

    Article  PubMed  CAS  Google Scholar 

  96. Cai Z, McCaslin PP (1992) Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate-and N-methyl-Daspartate-induced intracellular Ca’ levels in neuronal culture. Eur J Pharmacol 219: 53–57

    Article  PubMed  CAS  Google Scholar 

  97. Rothrock JF (1997) Clinical studies of valproate for migraine prophylaxis. Cephalalgia 17: 81–83

    Article  PubMed  CAS  Google Scholar 

  98. Loscher W, Bohme G, Schafer H, Kochen W (1981) Effect of metabolites of valproic acid on the metabolism of GABA in brain and brain nerve endings. Neuropharmacology 20: 1187–1192

    Article  PubMed  CAS  Google Scholar 

  99. Loscher W (1993) In vivo administration of valproate reduces the nerve terminal (synaptosomal) activity of GABA aminotransferase in discrete brain areas of rats. Neurosci Lett 160: 177–180

    Article  PubMed  CAS  Google Scholar 

  100. Cutrer FM, Limmroth V, Moskowitz MA (1997) Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia 17: 93–100

    Article  PubMed  CAS  Google Scholar 

  101. Van den Berg RJ, Kok P, Voskuyl RA (1993) Valproate and sodium currents in cultured hippocampal neurons. Exp Brain Res 93: 279–287

    PubMed  Google Scholar 

  102. Van Erp MG, Van Dongen AM, Van den Berg RJ (1990) Voltage-dependent action of valproate on potassium channels in frog node of Ranvier. Eur J Pharmacol 184: 151–161

    Article  PubMed  Google Scholar 

  103. Lee W S, Limmroth V, Ayata C et al (1995) Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol 116: 1661–1667

    Article  PubMed  CAS  Google Scholar 

  104. Cutrer FM, Limmroth V, Ayata G, Moskowitz MA (1995) Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br J Pharmacol 116: 3199–3204

    Article  PubMed  CAS  Google Scholar 

  105. Peroutka SJ (1997) Dopamine and migraine. Neurology 49: 650–656

    Article  PubMed  CAS  Google Scholar 

  106. Greenberg DA (1986) Calcium channel antagonists and the treatment of migraine. Clin Neuropharmacol 9: 311–328

    Article  PubMed  CAS  Google Scholar 

  107. Weizman R, Getslev V, Pankova IA et al (1999) Pharmacological interaction of the calcium channel blockers verapamil and flunarizine with the opioid system. Brain Res 818: 187–195

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Headache Unit, Department of Neurology, Fundación Hospital Alcorcón, Juan Carlos I University, Madrid, Spain

    Margarita Sánchez del Río

Authors
  1. Margarita Sánchez del Río
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA

    Egilius L. H. Spierings

  2. Headache Unit, Department of Neurology, Fundación Hospital Alcorcón Juan Carlos I University, Madrid, Spain

    Margarita Sánchez del Río

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Basel AG

About this chapter

Cite this chapter

Sánchez del Río, M. (2002). Inhibition of neurogenic inflammation in preventive migraine treatment. In: Spierings, E.L.H., Sánchez del Río, M. (eds) Migraine: A Neuroinflammatory Disease?. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8131-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8131-9_9

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9449-4

  • Online ISBN: 978-3-0348-8131-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation